Question:
How do you write HPI for The patient had a recent lab done and the lab results show folate level of >23.70 ng/mL (reference 3.0-13.0) and vitamin B12 of 790 pg/mL (reference 200-600) are both markedly elevated, creating a dangerous high-folate-low-vitamin B12 interaction syndrome. The patient shows functional iron deficiency with: Ferritin 25.9 ng/mL (low-normal), TIBC 490.8 ug/dL (elevated, reference 250-350), Transferrin saturation 19.72% (borderline low) and Macrocytosis (MCV 99.0 fL). Also, the patient has Stage 3a CKD with eGFR 57-69 mL/min/1.73 m² and BUN at the upper limit of normal (25 mg/dL). Additionally, the patient urinalysis shows positive nitrites and elevated leukocyte esterase (500 Leu/uL), and the culture show Bacteroides fragilis. The fasting glucose of 110 mg/dL is slightly above the ideal target of <110 mg/dL but represents substantial progress. The patient has achieved excellent glycemic improvement, with HbA1c dropping from 8.0% to 6.3% over three months on the current regimen of Lantus and Mounjaro. The patient Stage 3a CKD has important implications for medication management. The plan of care is for the patient to continue tirzepatide-it provides kidney protection independent of glycemic control. Continue tirzepatide (Mounjaro) and insulin glargine (Lantus) at current doses, discontinue Foltanx immediately. Need Assignment Help?